ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 853

Anti-TIF-1 Antibody Positivity Is Associated with a Five-Fold Increase in Cancer Risk in the Idiopathic Inflammatory Myopathies

Alexander Oldroyd1,2, Jamie C Sergeant1,3, Paul New4, Neil J. McHugh5,6, Zoe Betteridge5, Janine Lamb7, William Ollier7, Robert Cooper4,7,8 and Hector Chinoy2,9, 1Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, 2NIHR Manchester Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester, United Kingdom, 3Centre for Biostatistics, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, 4MRC/ARUK Centre for Integrated Research into Musculoskeletal Ageing, University of Liverpool, Liverpool, United Kingdom, 5Department of Pharmacy and Pharmacology, The University of Bath, Bath, United Kingdom, 6Royal National Hospital for Rheumatic Diseases, Bath, UK, Bath, United Kingdom, 7Division of Population Health, Health Services Research and Primary Care, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, 8Department of Rheumatology, Aintree University Hospital, Liverpool, United Kingdom, 9Department of Rheumatology, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Salford, United Kingdom

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: autoantibodies, Cancer, dermatomyositis and myositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Muscle Biology, Myositis and Myopathies

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose:

There is an increased cancer risk associated with the idiopathic inflammatory myopathies (IIM). Studies have identified that positivity for the autoantibody against transcriptional intermediary factor 1 (anti-TIF-1 Ab) confers an even greater cancer risk in the IIMs. Investigating the temporal relationship between anti-TIF-1 Ab positivity and cancer onset in a large longitudinal IIM cohort will be inform future cancer screening practice. This study aimed to characterise the temporal relationship between anti-TIF-1 Ab positivity and cancer onset in a large UK-based adult IIM cohort.

Methods:

Data from adults with a Bohan & Peter-verified diagnosis of IIM from the UKMYONET study were analysed. Anti-TIF-1 Ab (alpha and gamma serosubtype) positive and negative patients were included. Each patient was followed up until they either developed cancer or were censored due to death. UKMYONET recruitment began in 1999, and cancer occurrence linkage was carried out up until December 2016 through the UK Health and Social Care Information Centre. Cancer associated myositis (CAM) was defined as an incident cancer occurring three years either side of the onset of IIM. The cumulative incidence of cancer after IIM onset was estimated according to Kaplan-Meier methods for the anti-TIF-1 Ab positive and negative cohorts. Hazard ratios for the time to cancer diagnosis by anti-TIF-1 Ab positivity were calculated using a Cox-regression model adjusted for age, gender and smoking status.

Results:

Data from 711 IIM cases were analysed, with a total of 8009 person-years follow up (Table 1); 55 (8%) of the IIM cases were anti-TIF-1 Ab positive, and all had dermatomyositis. A higher proportion of the anti-TIF-1 Ab positive cohort developed CAM, compared to the anti-TIF-1 Ab negative cohort: 38% vs 8%. Even after only one year of follow up, the proportion of the anti-TIF-1 Ab positive patients developing cancer (27%) exceeded the three year proportion of the anti-TIF-1 Ab negative cohort (8%). Cox proportional modelling revealed that anti-TIF-1 Ab positivity was significantly associated with an increased hazard of an associated cancer following IIM onset: HR 3.4 (95% CI 2.2, 5.4). Breast (33%), ovarian (19%) and lymphoma (14%) were the three most common cancers in the anti-TIF-1 Ab positive patients, whereas breast (20%), bowel (14%), lung (6%) and cervix (6%) were the most common sites in anti-TIF-1 Ab negative patients.

Conclusion:

This study has helped to characterise the temporal relationship between anti-TIF-1 Ab positivity and cancer onset. The findings that earlier cancer onset is associated with anti-TIF-1 Ab positivity, and that associated cancer types differ, are potentially of clinical significance, and appear to suggest a specific cancer screening approach in anti-TIF-1 Ab positive patients.

Table 1 – Baseline demographics and time to cancer confirmation in anti-TIF-1 Ab positive and negative cohorts

Total cohort n = 711

Anti-TIF-1 Ab positive, = 55

Anti-TIF-1 negative, n = 656

Female (%)

438 (61.6)

44 (80.0)

394 (60.1)

Smokers (%)

237 (33.3)

17 (30.9)

220 (33.5)

CAM* (%)

72 (10.1)

21 (38.2)

51 (7.8)

Proportion of patients with cancer preceding IIM onset** (%)

36 (5.1)

7 (12.7)

29 (4.4)

Proportion of patients with cancer following IIM onset*** (%)

36 (5.1)

14 (25.5)

22 (3.4)

Median age at IIM onset (years, (IQR)

61.8 (51.9, 69.1)

62.3 (55.2, 65.9)

53.2 (42.6, 63.9)

Median age at cancer onset (years, IQR)

60.9 (50.4, 68.6)

60.3 (52.2, 67.2)

61.0 (50.4, 69.5)

Median time to cancer onset (years, IQR)

1.9 (0.0, 8.0)

0.8 (0.0, 2.2)

1.7 (0.0, 5.1)

Cumulative proportion with cancer onset in years after IIM onset (%, 95% CI):

0.5 year after IIM onset

6.2 (4.4, 7.9)

14.5 (4.7, 23.4)

5.5 (3.7, 7.2)

1 year after IIM onset

7.5 (5.5, 9.4)

27.3 (14.5, 38.1)

5.8 (4.0, 7.6)

2 years after IIM onset

9.0 (6.9, 11.1)

34.5 (20.7, 46.0)

6.9 (4.9, 8.8)

3 years after IIM onset

10.1 (7.9, 12.3)

38.2 (23.9, 49.8)

7.8 (5.7, 9.8)

*CAM = cancer associated myositis – cancer occurring within 3 years either side of an IIM onset

** Defined as cancer occurring less than 3 years prior to IIM onset

*** Defined as cancer occurring less than 3 years after IIM onset

IIM = idiopathic inflammatory myopathy

IQR = interquartile range

CI = confidence interval


Disclosure: A. Oldroyd, None; J. C. Sergeant, None; P. New, None; N. J. McHugh, None; Z. Betteridge, None; J. Lamb, None; W. Ollier, None; R. Cooper, None; H. Chinoy, Novartis Pharmaceutical Corporation, 5,Novartis Pharmaceutical Corporation, 2.

To cite this abstract in AMA style:

Oldroyd A, Sergeant JC, New P, McHugh NJ, Betteridge Z, Lamb J, Ollier W, Cooper R, Chinoy H. Anti-TIF-1 Antibody Positivity Is Associated with a Five-Fold Increase in Cancer Risk in the Idiopathic Inflammatory Myopathies [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/anti-tif-1-antibody-positivity-is-associated-with-a-five-fold-increase-in-cancer-risk-in-the-idiopathic-inflammatory-myopathies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-tif-1-antibody-positivity-is-associated-with-a-five-fold-increase-in-cancer-risk-in-the-idiopathic-inflammatory-myopathies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology